tag@treatmentactiongroup.org

TB

Treatment Action Group Lauds FDA Approval of First New Tuberculosis Drug in Half a Century

Treatment Action Group (TAG) applauds the accelerated approval today of bedaquiline, the first new approved drug to treat tuberculosis (TB) in over forty years, by the U.S. Food and Drug Administration (FDA). The drug has the potential to improve the treatment for multi-drug resistant (MDR) TB, a particularly deadly and hard to treat form of TB that affects over a million people worldwide, and from which only about half of patients who are treated recover.
Read more

Statement on Bedaquiline to the FDA

Statement of Mark Harrington, Executive Director, Treatment Action Group to the FDA Anti-Infective Drugs Advisory Committee (AIDAC) Hearing on the Use of Bedaquiline (TMC207) for Treatment of Multidrug-Resistant (MDR) Tuberculosis (TB)
Read more

Getting to Zero—Join the Movement!

By Colleen Daniels Tuberculosis (TB), a 40,000-year-old disease, still devastates communities although it has been preventable—and curable—for decades. In 2010, the World Health Organization (WHO) reported 8.8 million TB cases—1.4 million of them fatal—worldwide. TB is the leading cause of…

Read more

TAGline Fall 2012

TAG at 20 – Part II: On a Darkling Plain—The Years of Despair; Only Stronger U.S. Leadership Can End the AIDS Epidemic; Cure-Related Research at AIDS 2012; The Future of TB in the United States: Going, or Growing?; Getting to Zero—Join the Movement!; GeneXpert Rapid TB Test Price Reduced in Historic Agreement
Read more
Back To Top